Search
Descriptor English: Ipilimumab
Descriptor Spanish: Ipilimumab
Descriptor ipilimumab
Entry term(s) AcMo anti-CTL4 ipilimumab
Anti-CTLA-4 MAb Ipilimumab
MDX 010
MDX-010
MDX-CTLA-4
MDX010
Yervoy
Scope note: Anticuerpo monoclonal anti ANTÍGENO CTLA-4 indicado en el tratamiento de ciertos tipos de MELANOMA metastásico. Su mecanismo de acción incluye el bloqueo de la inhibición mediada por CTLA-4 de los LINFOCITOS CITOTÓXICOS T, lo que permite una destrucción más eficiente de las células tumorales objetivo.
Descriptor Portuguese: Ipilimumab
Descriptor French: Ipilimumab
Entry term(s): Anti CTLA 4 MAb Ipilimumab
Anti-CTLA-4 MAb Ipilimumab
Ipilimumab, Anti-CTLA-4 MAb
MDX 010
MDX CTLA 4
MDX-010
MDX-CTLA-4
MDX010
Yervoy
Tree number(s): D12.776.124.486.485.114.224.060.798
D12.776.124.790.651.114.224.060.798
D12.776.377.715.548.114.224.200.798
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D000074324
Scope note: An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.
Allowable Qualifiers: AD administration & dosage
AE adverse effects
AN analysis
BI biosynthesis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
DE drug effects
EC economics
GE genetics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PH physiology
PK pharmacokinetics
PO poisoning
RE radiation effects
TO toxicity
TU therapeutic use
UL ultrastructure
UR urine
Pharm Action: Antineoplastic Agents, Immunological
Public MeSH Note: 2018; IPILIMUMAB was indexed under ANTIBODIES, MONOCLONAL, 2012-2017
History Note: 2018(2012)
Related: CTLA-4 Antigen MeSH
DeCS ID: 57066
Unique ID: D000074324
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 2018/01/01
Date of Entry: 2017/07/11
Revision Date: 2017/06/20
Ipilimumab - Preferred
Concept UI M000626138
Scope note An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.
Preferred term Ipilimumab
Entry term(s) Anti CTLA 4 MAb Ipilimumab
Anti-CTLA-4 MAb Ipilimumab
Ipilimumab, Anti-CTLA-4 MAb
Yervoy - Narrower
Concept UI M0558172
Preferred term Yervoy
MDX 010 - Narrower
Concept UI M0495808
Preferred term MDX 010
Entry term(s) MDX-010
MDX010
MDX-CTLA-4 - Narrower
Concept UI M0495810
Preferred term MDX-CTLA-4
Entry term(s) MDX CTLA 4



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey